We are live on ! Find out more
NVS icon

Novartis

1,312 hedge funds and large institutions have $15.2B invested in Novartis in 2024 Q3 according to their latest regulatory filings, with 100 funds opening new positions, 415 increasing their positions, 480 reducing their positions, and 79 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more first-time investments, than exits

New positions opened: 100 | Existing positions closed: 79

4% more capital invested

Capital invested by funds: $14.7B → $15.2B (+$539M)

0% more funds holding

Funds holding: 1,3071,312 (+5)

0.25% less ownership

Funds ownership: 6.29%6.03% (-0.25%)

13% less funds holding in top 10

Funds holding in top 10: 1513 (-2)

14% less repeat investments, than reductions

Existing positions increased: 415 | Existing positions reduced: 480

42% less call options, than puts

Call options by funds: $171M | Put options by funds: $294M

Holders
1,312
Holders Change
+5
Holders Change %
+0.38%
% of All Funds
18.84%
Holding in Top 10
13
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-13.33%
% of All Funds
0.19%
New
100
Increased
415
Reduced
480
Closed
79
Calls
$171M
Puts
$294M
Net Calls
-$123M
Net Calls Change
-$96.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Creative Planning
51
Creative Planning
Kansas
$39.7M +$1.53M +13,486 +4%
RJFSA
52
Raymond James Financial Services Advisors
Florida
$38M -$2.77M -24,386 -7%
WFMPM
53
Woodley Farra Manion Portfolio Management
Indiana
$37.2M +$422K +3,721 +1%
SC
54
Saturna Capital
Washington
$36.6M -$953K -8,395 -3%
Cerity Partners
55
Cerity Partners
New York
$36.3M +$5.25M +46,232 +17%
JP Morgan Chase
56
JP Morgan Chase
New York
$35.9M -$651K -5,738 -2%
VanEck Associates
57
VanEck Associates
New York
$35.4M +$2.74M +24,123 +8%
Citigroup
58
Citigroup
New York
$33.8M +$4.84M +42,642 +17%
HighTower Advisors
59
HighTower Advisors
Illinois
$33.5M -$566K -4,988 -2%
FCI
60
Financial Counselors Inc
Kansas
$29.9M -$42.5K -375 -0.1%
GHA
61
GW Henssler & Associates
Georgia
$28.9M +$188K +1,653 +0.7%
Janney Montgomery Scott
62
Janney Montgomery Scott
Pennsylvania
$28.2M -$444K -3,913 -2%
US Bancorp
63
US Bancorp
Minnesota
$27.9M +$2.97M +26,150 +12%
OSAM
64
O'Shaughnessy Asset Management
Connecticut
$27.1M +$4.75M +41,859 +22%
MIM
65
Martin Investment Management
Florida
$27M +$647K +5,700 +2%
Mirae Asset Global Investments
66
Mirae Asset Global Investments
South Korea
$26.8M +$14.1M +124,111 +115%
OAM
67
Oppenheimer Asset Management
New York
$26.4M -$6.83M -60,212 -21%
TRSOTSOK
68
Teachers Retirement System of the State of Kentucky
Kentucky
$26.4M
FGI
69
Foresight Global Investors
New York
$25.9M +$6.07M +53,520 +31%
AssetMark Inc
70
AssetMark Inc
California
$25.8M +$1.17M +10,290 +5%
PNC Financial Services Group
71
PNC Financial Services Group
Pennsylvania
$25.4M -$251K -2,210 -1%
Stifel Financial
72
Stifel Financial
Missouri
$25.2M +$940K +8,284 +4%
BIP
73
Brandes Investment Partners
California
$24.6M -$1.19M -10,465 -5%
FFB
74
First Financial Bankshares
Texas
$24.2M -$253K -2,226 -1%
MIF
75
Mediolanum International Funds
Ireland
$24.1M +$23.5M +207,506 New

NVS Hedge Fund Activity: Q3 2024 in Review

1,312 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2024, worth a combined $15.2B — up 3.7% from $14.7B a quarter earlier.

Buyers outnumbered sellers: 100 funds opened new NVS positions and 79 closed out — a net gain of 21 holders — while 415 added to existing stakes and 480 trimmed.

The largest buyer was Dimensional Fund Advisors, adding an estimated $77.8M. The largest seller was Magnetar Financial, exiting entirely with an estimated $139M sold.

  • 1,312 institutional investors held Novartis (NVS) as of Q3 2024, up from 1,307 in Q2 2024.
  • Funds reported $15.2B of Novartis stock for Q3 2024, up 3.7% quarter-over-quarter.
  • 100 funds opened new Novartis positions in Q3 2024 and 79 closed out, a net change of +21 holders.
  • The largest Novartis buyer in Q3 2024 was Dimensional Fund Advisors, an estimated $77.8M added.
  • The largest Novartis seller in Q3 2024 was Magnetar Financial, an estimated $139M sold.

Based on aggregated 13F filings for Q3 2024.